The role of m6A RNA methylation in human cancer

By Xiaoyu Chen, Jing Zhang, Jinshui Zhu. Molecular Cancer, 2019

907 citations recorded by the source corpus.

N6-methyladenosine (m6A) is identified as the most common, abundant and conserved internal transcriptional modification, especially within eukaryotic messenger RNAs (mRNAs). M6A modification is installed by the m6A methyltransferases (METTL3/14, WTAP, RBM15/15B and KIAA1429, termed as “writers”), reverted by the demethylases (FTO and ALKBH5, termed as “erasers”) and recognized by m6A binding proteins (YTHDF1/2/3, IGF2BP1 and HNRNPA2B1, termed as “readers”). Acumulating evidence shows that, m6A RNA methylation has an outsize effect on RNA production/metabolism and participates in the pathogenesis of multiple diseases including cancers. Until now, the molecular mechanisms underlying m6A RNA methylation in various tumors have not been comprehensively clarified. In this review, we mainly summarize the recent advances in biological function of m6A modifications in human cancer and discuss the potential therapeutic strategies.

Subfields: Electrical and Electronic Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fc4256fc403b03bb162edea2614735b4ebdb5a28

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Gang Yin
2. Anqi Wu
3. Liuer He
4. Huiyu Li
5. Guang Shu
6. Yulong Peng

Citations in the corpus

• Functions of N6-methyladenosine and its role in cancer (2019, background): ““Readers” recognize and bind m6A sites, leading to different destinies of target RNA [74, 75] (Fig.”